Martin Reck, MD, PhD of the LungenClinic Grosshansdorf, Grosshansdorf, Germany, highlights the importance of the randomized Phase III JAVELIN Lung 100 trial in non-small-cell lung cancer (NSCLC) (NCT02576574). This trial is investigating the new immune checkpoint inhibitor, the programmed death-1 receptor ligand (PD-L1), avelumab, compared to platinum-based chemotherapy in patients with metastatic or recurrent PD-L1-positive NSCLC who have never been treated before. This is an on-going trial and results are expected in early 2017. Finally, he mentions that the primary endpoint is progression-free survival (PFS) and further, they will look at overall survival (OS), tumor response and tolerability, which is crucial for patients with NSCLC. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.